Adarsh Vennepureddy, MD
Hematology & Oncology · Sandusky, OHNPI 1104265156
Payments from drug & device makers
Across 120 payments — averaging $530.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$56K
- Seagen Inc.$1K
- AstraZeneca$1K
- Servier Pharmaceuticals LLC$1K
- Exelixis Inc.$740
- Beigene USA, Inc.$675
- plus $2K from 33 others
What the payments were for
- Consulting fees$4,29555%
- Food & beverage$3,39444%
- Education$851%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 18 | $56,110 |
| Seagen Inc. | 4 | $1,388 |
| AstraZeneca | 11 | $1,351 |
| Servier Pharmaceuticals LLC | 1 | $1,320 |
| Exelixis Inc. | 1 | $740 |
| Beigene USA, Inc. | 1 | $675 |
| AbbVie | 5 | $200 |
| GSK | 5 | $188 |
| Novartis | 9 | $167 |
| Sanofi | 3 | $144 |
| Pfizer | 2 | $131 |
| Genentech USA, Inc. | 2 | $121 |
| Lilly USA, LLC | 6 | $109 |
| Jazz Pharmaceuticals Inc. | 5 | $105 |
| Pharmacyclics LLC, An Abbvie Company | 5 | $95 |
| Astellas Pharma US Inc | 4 | $85 |
| E.r. Squibb & Sons, L.L.C. | 4 | $69 |
| Bristol Myers Squibb | 4 | $65 |
| Gilead | 3 | $62 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $56 |
| Myovant Sciences Inc. | 2 | $50 |
| Array Biopharma Inc | 3 | $49 |
| EMD Serono, Inc. | 1 | $44 |
| Amgen | 2 | $38 |
| Morphosys, US Inc. | 2 | $33 |
| Boehringer Ingelheim | 1 | $30 |
| Incyte Corporation | 2 | $29 |
| Daiichi Sankyo Inc. | 1 | $23 |
| Medtronic | 1 | $21 |
| Sumitomo Pharma America, Inc. | 1 | $21 |
| Tempus AI, Inc | 1 | $20 |
| Lexicon Pharmaceuticals, Inc. | 1 | $19 |
| Bayer | 1 | $18 |
| Eisai Inc. | 1 | $17 |
| Deciphera Pharmaceuticals Inc. | 1 | $16 |
| Johnson & Johnson | 1 | $15 |
| Pharmacosmos Therapeutics Inc. | 1 | $15 |
| Rigel Pharmaceuticals, Inc. | 1 | $14 |
| Mylan Institutional Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$63,671 in reported general payments places this provider in the 65th percentile of 450 hematology & oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 59 | $680,662 |
| RevlimidLenalidomide | 31 | $405,687 |
| CabometyxCabozantinib S-Malate | 15 | $381,619 |
| ImbruvicaIbrutinib | 15 | $261,192 |
| Lenalidomide | 25 | $253,959 |
| NubeqaDarolutamide | 17 | $216,330 |
| CalquenceAcalabrutinib Maleate | 14 | $207,072 |
| IbrancePalbociclib | 13 | $203,622 |
| EliquisApixaban | 179 | $143,133 |
| Abiraterone Acetate | 59 | $82,101 |
| XareltoRivaroxaban | 54 | $57,963 |
| Ondansetron Hcl | 55 | $4,398 |
| Hydroxyurea | 81 | $1,707 |
| Potassium Chloride | 64 | $1,425 |
| Dexamethasone | 82 | $1,167 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi | $85 | $680,66259 claims |
| Bristol Myers SquibbRevlimid | $65 | $405,68731 claims |
| Exelixis Inc.Cabometyx | $740 | $381,61915 claims |
| PfizerIbrance, Eliquis | $131 | $346,755192 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $95 | $261,19215 claims |
| BayerNubeqa | $18 | $216,33017 claims |
| AstraZenecaCalquence | $1,351 | $207,07214 claims |
| Johnson & JohnsonXarelto | $15 | $57,96354 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 450 hematology & oncology providers in Ohio.
Other hematology & oncology in Sandusky
- Kasra KaramlouSandusky$2M
- Afshin DowlatiCleveland$25.1M
- Brian HillCleveland$11.6M
- Trisha Wise-DraperCincinnati$9.8M
- Davendra SohalCincinnati$8.6M
- Christopher HoimesCleveland$7.5M
- Balazs HalmosCleveland$7M
- David WaterhouseCincinnati$5.7M
- Dale ShepardCleveland$5.1M
- Paolo CaimiCleveland$4.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.